213 related articles for article (PubMed ID: 26873728)
1. Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.
Arpin CC; Mac S; Jiang Y; Cheng H; Grimard M; Page BD; Kamocka MM; Haftchenary S; Su H; Ball DP; Rosa DA; Lai PS; Gómez-Biagi RF; Ali AM; Rana R; Hanenberg H; Kerman K; McElyea KC; Sandusky GE; Gunning PT; Fishel ML
Mol Cancer Ther; 2016 May; 15(5):794-805. PubMed ID: 26873728
[TBL] [Abstract][Full Text] [Related]
2. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
[TBL] [Abstract][Full Text] [Related]
3. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
4. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Lin L; Hutzen B; Zuo M; Ball S; Deangelis S; Foust E; Pandit B; Ihnat MA; Shenoy SS; Kulp S; Li PK; Li C; Fuchs J; Lin J
Cancer Res; 2010 Mar; 70(6):2445-54. PubMed ID: 20215512
[TBL] [Abstract][Full Text] [Related]
5. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
Pathania D; Kuang Y; Sechi M; Neamati N
Br J Pharmacol; 2015 Jan; 172(1):50-63. PubMed ID: 25047070
[TBL] [Abstract][Full Text] [Related]
7. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
8. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
9. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
Murone M; Vaslin Chessex A; Attinger A; Ramachandra R; Shetty SJ; Daginakatte G; Sengupta S; Marappan S; Dhodheri S; Rigotti S; Bachhav Y; Brienza S; Traxler P; Lang M; Aguet M; Zoete V; Michielin O; Nicholas C; Johnson FM; Ramachandra M; McAllister A
Mol Cancer Ther; 2016 Oct; 15(10):2334-2343. PubMed ID: 27439479
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701.
Nishisaka F; Taniguchi K; Tsugane M; Hirata G; Takagi A; Asakawa N; Kurita A; Takahashi H; Ogo N; Shishido Y; Asai A
Cancer Sci; 2020 May; 111(5):1774-1784. PubMed ID: 32112605
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells.
Nam S; Wen W; Schroeder A; Herrmann A; Yu H; Cheng X; Merz KH; Eisenbrand G; Li H; Yuan YC; Jove R
Mol Oncol; 2013 Jun; 7(3):369-78. PubMed ID: 23206899
[TBL] [Abstract][Full Text] [Related]
12. Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth.
Li X; Ma H; Li L; Chen Y; Sun X; Dong Z; Liu JY; Zhu W; Zhang JT
Oncogene; 2018 May; 37(18):2469-2480. PubMed ID: 29456240
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
14. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
Huang Q; Zhong Y; Li B; Ouyang S; Deng L; Mo J; Shi S; Lv N; Wu R; Liu P; Hu W; Zhang X; Wang Y
Eur J Med Chem; 2021 Oct; 221():113525. PubMed ID: 34000483
[TBL] [Abstract][Full Text] [Related]
15. Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer.
Chen H; Zhou W; Bian A; Zhang Q; Miao Y; Yin X; Ye J; Xu S; Ti C; Sun Z; Zheng J; Chen Y; Liu M; Yi Z
Clin Cancer Res; 2023 Feb; 29(4):815-830. PubMed ID: 36374556
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.
Adamska A; Domenichini A; Capone E; Damiani V; Akkaya BG; Linton KJ; Di Sebastiano P; Chen X; Keeton AB; Ramirez-Alcantara V; Maxuitenko Y; Piazza GA; De Laurenzi V; Sala G; Falasca M
J Exp Clin Cancer Res; 2019 Aug; 38(1):312. PubMed ID: 31378204
[TBL] [Abstract][Full Text] [Related]
17. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors.
Gao D; Jin N; Fu Y; Zhu Y; Wang Y; Wang T; Chen Y; Zhang M; Xiao Q; Huang M; Li Y
Eur J Med Chem; 2021 Apr; 216():113333. PubMed ID: 33689932
[TBL] [Abstract][Full Text] [Related]
18. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
Zhang Z; Wang F; Du C; Guo H; Ma L; Liu X; Kornmann M; Tian X; Yang Y
Cancer Lett; 2017 Aug; 402():213-224. PubMed ID: 28602977
[TBL] [Abstract][Full Text] [Related]
19. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain.
Page BD; Fletcher S; Yue P; Li Z; Zhang X; Sharmeen S; Datti A; Wrana JL; Trudel S; Schimmer AD; Turkson J; Gunning PT
Bioorg Med Chem Lett; 2011 Sep; 21(18):5605-9. PubMed ID: 21788134
[TBL] [Abstract][Full Text] [Related]
20. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
Zhang W; Guo J; Li S; Ma T; Xu D; Han C; Liu F; Yu W; Kong L
Sci Rep; 2017 Apr; 7():46352. PubMed ID: 28397855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
